Cullen Enhanced Equity Income ETF’s 4.25% Medtronic Stake Backed by $550M Acquisition
Cullen Enhanced Equity Income ETF holds a 4.25% stake in Medtronic, which announced a $550 million acquisition of Scientia Vascular to enhance its neurovascular portfolio. The deal, set to close in H1 fiscal 2027, is projected to be minimally dilutive in 2027 and accretive thereafter.
1. Acquisition Terms and Strategic Rationale
Medtronic will pay $550 million upfront for Scientia Vascular, with additional undisclosed earn-out and milestone payments pending. Scientia’s 310 employees and its portfolio of guidewires and catheters will integrate into Medtronic’s neurovascular offerings to streamline procedural workflows.
2. Expected Financial Impact on Medtronic
The acquisition is scheduled to close in the first half of fiscal 2027 and is expected to be minimally dilutive to adjusted EPS in fiscal 2027 before becoming accretive in subsequent years. Medtronic leadership anticipates that the combined neurovascular portfolio will drive long-term revenue growth.
3. Implications for DIVP Portfolio
With Medtronic representing 4.25% of the ETF, the acquisition’s success could boost NAV returns for Cullen Enhanced Equity Income ETF investors. Potential volatility in Medtronic shares may introduce short-term risk, while strategic portfolio expansion supports medium-term income objectives.